FDA approves Roivant's Lisraya for treatment of dermatomyositis.
The FDA has approved Roivant's drug Lisraya (brepocitinib) for the treatment of dermatomyositis. The approval is national in scope across the United States. Patient access and real-world effectiveness are not yet known. According to the drugmaker Roivant, an estimated 40,000 to 70,000 people in the U.S. have the condition.
Why it matters
This provides a new approved treatment option for people with the rare autoimmune disease dermatomyositis.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news